Montreal, Canada
Nomic Bio, known as "The Protein Profiling Company", was founded in 2017 with a mission to simplify biological measurement and make proteomics accessible, scalable, and routine. Based in Canada, the company operates at the intersection of Biotechnology, Health Care, and Marketing.
Nomic's proprietary nELISA® technology provides large-scale, quantitative, and cost-effective protein data aimed at accelerating drug and biomarker discovery, development, and translation. The end-to-end service offered by Nomic integrates seamlessly into various stages of drug research through flexible content, expert support, and analysis-ready outputs.
The company recently secured a $42.00M Series B funding round on 01 September 2024, showcasing strong investor confidence. Noteworthy investors in this round include Real Ventures, Lux Capital, Amplitude Ventures, SR One, and AVANT BIO. Nomic Bio is well-positioned to make proteomics essential in modern biology.
